Seven-year efficacy and safety outcomes of Bulkamid for the treatment of stress urinary incontinence.
Bulkamid
bulking agents
long-term follow-up
mixed urinary incontinence
stress urinary incontinence
Journal
Neurourology and urodynamics
ISSN: 1520-6777
Titre abrégé: Neurourol Urodyn
Pays: United States
ID NLM: 8303326
Informations de publication
Date de publication:
01 2021
01 2021
Historique:
received:
28
06
2020
revised:
31
10
2020
accepted:
18
11
2020
pubmed:
8
1
2021
medline:
12
6
2021
entrez:
7
1
2021
Statut:
ppublish
Résumé
Bulking agents are a minimally invasive treatment option for women with stress urinary incontinence (SUI) or stress-predominant mixed urinary incontinence (MUI). The aim of this study was to evaluate long-term efficacy and safety following treatment with Bulkamid as a primary procedure for SUI or stress-predominant MUI. This was an Institutional Review Board-approved single-center retrospective study of female patients with SUI or stress-predominant MUI who had undergone injection with Bulkamid since 2005 and had completed 7 years of follow up. The primary endpoint was patient satisfaction measured on a four-point scale as cured, improved, unchanged, or worse. Secondary outcomes included the number of incontinence pads used, International Consultation on Incontinence Questionnaire-Short Form (ICIQ-UI SF) scores, Visual Analog Scale Quality of Life (VAS QoL), reinjection rates, and perioperative and postoperative complications. A total of 1,200 patients were treated with Bulkamid since 2005 and of these, 388 (32.3%) had completed 7 years of follow-up. A total of 67.1% of the patients reported feeling cured or improved if Bulkamid was a primary procedure, 11.1% reported no change, and 2.3% reported worsening of incontinence. A total of 19.5% of patients received a subsequent other incontinence procedure. The ICIQ-UI SF was reduced by 8.6 points. VAS QoL improved by a mean of 4.3 points. Postoperative complications were transient. Prolonged bladder emptying time was reported in 15.3% of patients and urinary tract infection in 3.5%. Bulkamid injections are an effective and safe first-line treatment option for women with SUI or stress-predominant MUI providing durable outcomes at 7 years.
Identifiants
pubmed: 33410544
doi: 10.1002/nau.24589
pmc: PMC7839440
doi:
Substances chimiques
Acrylic Resins
0
Biocompatible Materials
0
Bulkamid
0
Hydrogels
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
502-508Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2021 The Authors. Neurourology and Urodynamics published by Wiley Periodicals LLC.
Références
Int Braz J Urol. 2019 Sep-Oct;45(5):989-998
pubmed: 31626522
Eur J Obstet Gynecol Reprod Biol. 2016 Dec;207:68-72
pubmed: 27825030
J Endourol. 2006 Dec;20(12):1082-6
pubmed: 17206907
Res Rep Urol. 2019 Nov 12;11:299-310
pubmed: 31815111
Neurourol Urodyn. 2017 Mar;36(3):722-726
pubmed: 27037856
Int Urogynecol J. 2010 Jan;21(1):5-26
pubmed: 19937315
Int Urogynecol J. 2016 Feb;27(2):301-5
pubmed: 26342812
J Urol. 2014 Sep;192(3):843-9
pubmed: 24704117
BJU Int. 2019 Feb;123(2):353-359
pubmed: 30253026
Surg Gynecol Obstet. 1973 Apr;136(4):547-54
pubmed: 4570309
J Low Genit Tract Dis. 2002 Oct;6(4):239-43
pubmed: 17051030
J Urol. 2020 Feb;203(2):372-378
pubmed: 31479396
Neurourol Urodyn. 2004;23(4):322-30
pubmed: 15227649
Cent European J Urol. 2015;68(3):334-8
pubmed: 26568877
Neurourol Urodyn. 2008;27(8):789-92
pubmed: 18642372
Neurourol Urodyn. 2015 Feb;34(2):183-7
pubmed: 24273137
Dermatol Surg. 2008 Jun;34 Suppl 1:S68-77; discussion S77
pubmed: 18547185
Neurourol Urodyn. 2021 Jan;40(1):502-508
pubmed: 33410544
Menopause. 2018 Jun;25(6):663-667
pubmed: 29557846
Int Urogynecol J. 2017 Sep;28(9):1275-1284
pubmed: 28220200
Int Urogynecol J. 2010 Dec;21(12):1471-7
pubmed: 20645077
BJU Int. 2006 Jul;98(1):100-4
pubmed: 16831152
Arch Gynecol Obstet. 2013 Jul;288(1):131-7
pubmed: 23371485
Cent European J Urol. 2015;68(4):428-33
pubmed: 26855795